Susquehanna International Group LLP acquired a new stake in shares of DURECT Co. (NASDAQ:DRRX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,954 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Susquehanna International […]
DURECT Co. (NASDAQ:DRRX – Get Rating) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 424,200 shares, an increase of 13.6% from the March 15th total of 373,300 shares. Based on an average trading volume of 104,600 shares, the short-interest ratio is presently […]
Regis Management CO LLC cut its position in DURECT Co. (NASDAQ:DRRX – Get Rating) by 90.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,425 shares of the specialty pharmaceutical company’s stock after selling 120,825 shares during the quarter. Regis Management […]
Analysts expect DURECT Co. (NASDAQ:DRRX – Get Rating) to post ($0.04) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for DURECT’s earnings. DURECT also reported earnings per share of ($0.04) during the same quarter last year. The company is scheduled to announce its next quarterly […]
StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a note issued to investors on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock. Separately, Zacks Investment Research lowered shares of DURECT from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. […]